Altamira Therapeutics Ltd. CYTOF
0.07
0.00
0.00%
as of 24 Sep
- Market cap
- $1.1M
- P/E
- 0.0×
Follow CYTOF
| Older periods | Jun '22 | Jun '23 | Jun '24 | Jun '25 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(514.91%) | (385.74%) | 0.00% | 0.00% | |
| (236.82%) | (214.75%) | 0.00% | 0.00% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
426.90% | 807.49% | 0.00% | 0.00% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(38.84) | (6.99) | 0.00 | 0.00 | |
Free Cash Flow |
(30.09) | (29.37) | (27.16) | (19.09) | |
Capital Expenditures |
(5.68) | — | — | — | |
Piotroski F-Score |
1.00 | 1.00 | — | — | |
| Other line items | |||||
Cash ROIC |
(176.11%) | (1,722.06%) | (408.62%) | (423.46%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
1.86 | 2.37 | 0.00 | 0.00 | |
Inventory Turnover |
0.00 | 0.00 | — | — | |
Average Days of Payables |
313.21 | 192.55 | 0.00 | 0.00 | |
Days of Inventory on Hand |
0.00 | 0.00 | — | — | |
Tax Rate |
0.00 | 0.00 | — | — | |
Research and Development Expense of Revenue |
0.00% | 0.00% | — | — | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | — | — | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.74 | 0.90 | 0.00 | 0.00 | |
Depreciation/Fixed assets |
0.29 | 0.00 | 0.00 | 2.60 | |
Capex/Depreciation |
(36.63) | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | — | — | |
Operating CF per Share |
(31.50) | (6.99) | 0.00 | 0.00 | |
Capex per Share |
(7.34) | 0.00 | — | — | |
Capex to Sales |
0.00 | — | — | — | |
Net Profit Margin |
0.00% | 0.00% | — | — |
Columns are period end dates